Metastasis-free survival of uveal melanoma by tumour size category based on The Cancer Genome Atlas (TCGA) classification in 1001 cases

被引:1
|
作者
Bansal, Rolika [1 ]
Sener, Hidayet [1 ]
Ganguly, Arupa [2 ]
Shields, Jerry A. [1 ]
Shields, Carol L. [1 ]
机构
[1] Thomas Jefferson Univ, Wills Eye Hosp, Ocular Oncol Serv, 840 Walnut St,Suite 1440, Philadelphia, PA 19107 USA
[2] Univ Penn, Sch Med, Dept Genet, Philadelphia, PA USA
来源
关键词
melanoma; TCGA; The Cancer Genome Atlas; tumour size category; uvea; MONOSOMY; 3; PROGNOSTICATION; HETEROGENEITY; FEATURES; PROFILE; BIOPSY;
D O I
10.1111/ceo.14446
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background: Uveal melanoma (UM) can be classified by tumour size category and by The Cancer Genome Atlas (TCGA) groups (cytogenetic-based, 4-category prognostic classification into Groups A-D). This study was conducted to assess impact on metastasis-free survival (MFS) in UM by tumour size category based on correlation with TCGA classification. Methods: Retrospective analysis of 1001 cases categorised as small (0.0-3.0 mm), medium (3.1-8.0 mm) and large (>= 8.1 mm), grouped by TCGA classification. Results: Of 1001 cases, TCGA Groups (A/B/C/D) included small (n = 270, 75%/11%/13%/1%), medium (n = 503, 46%/14%/27%/13%) and large (n = 228, 23%/19%/38%/20%) UM. The 5-and 10-year Kaplan-Meier MFS for small UM revealed Group A (98%, 98%), Group B (100%, 100%), Group C (86%, NA) and Group D (100%, NA). For medium UM, the values dropped with Group A (95%, 93%), Group B (90%, 90%), Group C (68%, 38%), and Group D (44%, NA). For large UM, the values dropped further with Group A (94%, 86%), Group B (85%, NA), Group C (40%, 28%), and Group D (23%, NA). Additionally, a comparison (small vs. medium vs. large tumour size category) revealed TCGA low-risk grouping (Groups A or B) in 86% vs. 60% vs. 58% cases with UM. Conclusion: By tumour size category, favourable cytogenetics (Groups A or B) is found in 86% of small tumours, 60% of medium tumours, and 58% of large tumours. The MFS at 10 years for favourable cytogenetics was 98% for small tumours, 92% for medium tumours, and 54% for large tumours. Tumour size category can serve as a surrogate for TCGA.
引用
收藏
页码:175 / 183
页数:9
相关论文
共 35 条
  • [31] Histo-Genomic Review of Digital Diagnostic Slides from the Cancer Genome Reveals Differentially Expressed Cellular Pigmentation Genes that are Correlated to Uveal Melanoma Pigmentation Intensity and its Association to Poor Prognosis Factors and Progression-Free Survival
    Lando, Leonardo
    Echelard, Philippe
    Nguyen, Anne Xuan-Lan
    Capo-Chichi, Jose-Mario
    Trinh, Vincent Quoc-Huy
    LABORATORY INVESTIGATION, 2019, 99
  • [32] Histo-Genomic Review of Digital Diagnostic Slides from the Cancer Genome Reveals Differentially Expressed Cellular Pigmentation Genes that are Correlated to Uveal Melanoma Pigmentation Intensity and its Association to Poor Prognosis Factors and Progression-Free Survival
    Lando, Leonardo
    Echelard, Philippe
    Nguyen, Anne Xuan-Lan
    Capo-Chichi, Jose-Mario
    Trinh, Vincent Quoc-Huy
    MODERN PATHOLOGY, 2019, 32
  • [33] Breast conserving therapy versus mastectomy in T1-2N2 stage breast cancer: A population based study on 10-year overall, relative and distant metastasis-free survival in 3,071 patients
    Van Maaren, M. C.
    De Munck, L.
    Jobsen, J. J.
    Poortmans, P.
    De Bock, G. H.
    Siesling, S.
    Strobbe, L. J. A.
    EUROPEAN JOURNAL OF CANCER, 2016, 57 : S69 - S69
  • [34] Breast-conserving therapy versus mastectomy in T1-2N2 stage breast cancer: a population-based study on 10-year overall, relative, and distant metastasis-free survival in 3071 patients
    van Maaren, M. C.
    de Munck, L.
    Jobsen, J. J.
    Poortmans, P.
    de Bock, G. H.
    Siesling, S.
    Strobbe, L. J. A.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 160 (03) : 511 - 521
  • [35] Breast-conserving therapy versus mastectomy in T1-2N2 stage breast cancer: a population-based study on 10-year overall, relative, and distant metastasis-free survival in 3071 patients
    M. C. van Maaren
    L. de Munck
    J. J. Jobsen
    P. Poortmans
    G. H. de Bock
    S. Siesling
    L. J. A. Strobbe
    Breast Cancer Research and Treatment, 2016, 160 : 511 - 521